Pharmaceutical Innovation

The pharmaceutical industry worldwide is a rapidly burgeoning industry contributing to growth of gross domestic product and employment. Technological change in this field has been very rapid, with many new products being introduced. For this reason in part, health care budgets throughout the world have increased dramatically, eliciting growing pressures for cost containment. This book explores four important issues in pharmaceutical innovations: (1) the industry structure of pharmaceutical innovation; (2) incentives for correcting market failures in allocating resources for research and development; (3) competition and marketing; and (4) public evaluation of the benefits and costs of innovation. The lessons are applicable to countries all over the world, at all levels of economic development. By discussing existing evidence this book proposes incentive arrangements to accomplish social objectives.

ISBN 0521874904   Pages 346 ISBN13 9780521874908 (What's this?)   Volumes 1 Publisher Cambridge University Press   Weight (grammes) 602 Imprint Cambridge University Press   Published in Cambridge Format Hardback   Height (mm) 228 Publication date 30 Apr 2007   Width (mm) 152 Library of Congress RA401.A1 P43 2007   Spine width (mm) 26 DEWEY 338.476151   Academic level Professional / Scholarly DEWEY edition DC22

1		Introduction by Frank A. Sloan and Chee-Ruey Hsieh		1
Pt. I		The industry structure of pharmaceutical innovation
2		The pharmaceutical sector in health care by Uwe E. Reinhardt		25
3		The economics of research and development in the pharmaceutical industry by William S. Comanor		54
Pt. II		Structuring incentives for research and development
4		Drugs for neglected diseases : new incentives for innovation by Aidan Hollis		75
5		When patents fail : finding new drugs for the developing world by Stephen M. Maurer		91
6		Implementing a public subsidy for vaccines by Frank A. Sloan and Charles E. Eesley		107
7		Ensuring the future supply of vaccines : is a national vaccine authority the answer? by Frank R. Lichtenberg		127
Pt. III		Competition and marketing
8		Competition between generic and branded drugs by Henry Grabowski		153
9		The United States' experience with direct-to-consumer advertising of prescription drugs : what have we learned? by Ernst R. Berndt		174
Pt. IV		Public evaluation of the benefits and costs of innovation
10		Measures of costs and benefits for drugs in cost-effectiveness analysis by Mark V. Pauly		199
11		Using economic evaluation in reimbursement decisions for health technologies : lessons from international experience by Michael Drummond		215
12		Pharmaceutical spending and health outcomes by Pierre-Yves Cremieux and Denise Jarvinen and Genia Long and Phil Merrigan		226
13		Pharmaceutical innovation and health outcomes : empirical evidence from Taiwan by Chee-Ruey Hsieh and Kuang-Ta Vance Lo and Yichen Hong and Ya-Chen Tina Shih		242
14		Conclusions and policy implications by Frank A. Sloan and Chee-Ruey Hsieh		262

"The second section (chapters 4-7) provides the real meat of the book. The authors do an outstanding job of making a compelling case for formulating incentives for innovation based on societal needs." - JAMA

 Be the first to write a customer review